By Mike Montemarano, Associate Editor10.05.21
At Natural Products Expo East 2021, which took place in Philadelphia, PA in September, Todd Harrison and Claudia Lewis, both partners at Venable LLP, discussed a collection of anticipated regulatory and legal developments on the horizon. Also up for discussion were some of the ongoing impacts that the COVID-19 pandemic has had on the regulatory status of a variety of dietary ingredients and finished products.
COVID-19 and Regulatory State of Affairs
Between a degree of flexibility offered by the U.S. Food and Drug Administration (FDA), and developments in the enforcement of health claims, the nutraceuticals industry should be aware of a number of key developments, which changes might last, and which adjustments are intended to be temporary.
Due to supply shortages experienced intermittently since the pandemic began, FDA has been more flexible with supply chain issues than before; while many changes in enforcement discretion were intended to be temporary, some may last, Harrison said.
For example, FDA has provided exceptions relevant to food and beverage market, now a
COVID-19 and Regulatory State of Affairs
Between a degree of flexibility offered by the U.S. Food and Drug Administration (FDA), and developments in the enforcement of health claims, the nutraceuticals industry should be aware of a number of key developments, which changes might last, and which adjustments are intended to be temporary.
Due to supply shortages experienced intermittently since the pandemic began, FDA has been more flexible with supply chain issues than before; while many changes in enforcement discretion were intended to be temporary, some may last, Harrison said.
For example, FDA has provided exceptions relevant to food and beverage market, now a
Continue reading this story and get 24/7 access to Nutraceuticals World for FREE
FREE SUBSCRIPTION
